Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.35 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.35 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.32 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.32 |
| ▸ | PYGL | P06737 | 2/20 | 0.31 |
| ▸ | PYGB | P11216 | 2/20 | 0.31 |
| ▸ | PYGM | P11217 | 1/20 | 0.31 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.30 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL552610 | 0.90 | SLC28A1 (0.41) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL31280115 | 0.86 | SLC28A1 (0.39) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL17728070 | 0.85 | SLC28A1 (0.38) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL17065225 | 0.83 | SLC28A1 (0.34) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL6754600 | 0.82 | SLC28A1 (0.36) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL7611046 | 0.82 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL5964454 | 0.80 | SLC28A1 (0.36) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL29780672 | 0.78 | P2RY14 (0.36) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL28843545 | 0.77 | SLC28A1 (0.37) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL28843518 | 0.76 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522658-B2 | Anti-CD79 chimeric antigen receptors, CAR-T cells, and uses thereof | JANSSEN BIOTECH, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250340937-A1 | COLORECTAL CANCER ASSOCIATED CIRCULATING NUCLEIC ACID BIOMARKERS | CHRONIX BIOMEDICAL (US) | 2025-11-06 | — | — | US | disclosed |
| US-12460001-B2 | Proteins comprising CD3 antigen binding domains and uses thereof | JANSSEN BIOTECH, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12359252-B2 | Colorectal cancer associated circulating nucleic acid biomarkers | CHRONIX BIOMEDICAL (US) | 2025-07-15 | — | — | US | disclosed |
| WO-2025125630-A1 | METHOD FOR BIOPROTAC DESIGN | MEDIMMUNE LIMITED (GB) | 2025-06-19 | — | — | WO | disclosed |
| US-20250145711-A1 | PROTEINS COMPRISING CD3 ANTIGEN BINDING DOMAINS AND USES THEREOF | JANSSEN BIOTECH INC (US) | 2025-05-08 | — | — | US | disclosed |
| US-20250066510-A1 | GUCY2C ANTIBODIES AND USES THEREOF | JANSSEN BIOTECH, INC. | 2025-02-27 | — | — | US | disclosed |
| US-20250059600-A1 | MASS BASED DETECTION OF PCR AMPLICONS | ROCHE MOLECULAR SYSTEMS, INC. | 2025-02-20 | — | — | US | disclosed |
| WO-2025034715-A1 | GUCY2C ANTIBODIES AND USES THEREOF | JANSSEN BIOTECH, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| US-20240425603-A1 | ANTI-VEGFR1 ANTIBODIES AND THEIR USES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2024-12-26 | — | — | US | disclosed |
| WO-2002054939-A2 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING NEUROPSYCHIATRIC DISORDERS SUCH AS SCHIZOPHRENIA | MILLENNIUM PHARM INC (US) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002051868-A2 | METHODS AND MATERIALS RELATING TO STEM CELL GROWTH FACTOR-LIKE POLYPEPTIDES AND POLYNUCLEOTIDES | KIRIN BEER KABUSHIKI KAISHA (US) | 2002-07-04 | — | — | WO | disclosed |
| WO-2002040674-A2 | '67118', '67067' AND '62092', HUMAN PROTEINS AND METHODS OF USE THEREOF | MILLENIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| WO-2001081416-A2 | HUMAN ION CHANNEL AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-11-01 | — | — | WO | disclosed |
| WO-2001072280-A2 | MICROSPHERES FOR GENE THERAPY | BIOSPHERE MEDICAL INC. (US) | 2001-10-04 | — | — | WO | disclosed |
| WO-2001062911-A2 | ANTISENSE AND CATALYTICALLY ACTING NUCLEIC ACID MOLECULES TARGETED TO GRB2- RELATED WITH INSERT DOMAIN (GRID) PROTEINS AND THEIR USES | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001059117-A2 | SEVEN-TRANSMEMBRANE PROTEINS/G-PROTEIN COUPLED RECEPTORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-08-16 | — | — | WO | disclosed |
| WO-2000060085-A1 | FIBROBLAST GROWTH FACTOR-20 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-1007735-A1 | ANTI-SENSE OLIGONUCLEOTIDE PHARMACOLOGICAL AGENTS | TM Technologies Inc. (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1998037240-A1 | ANTI-SENSE OLIGONUCLEOTIDE PHARMACOLOGICAL AGENTS | TM TECHNOLOGIES, INC. (US) | 1998-08-27 | — | — | WO | disclosed |